Forum Pharmaceuticals, a biopharmaceutical company focused on the development and delivery of innovative medicines to treat serious brain diseases, has relocated its corporate headquarters to a 112,500-square-foot, state-of-the-art facility located in Waltham, Mass. The move consolidates Forum’s operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Previously, Forum conducted business from two locations in Watertown, Mass. and Brighton, Mass. The company also maintains a small European office in the Netherlands.
“We are excited to be located under one roof in Waltham, as it facilitates daily interaction of our development and commercial teams with research scientists to drive continued innovation in Forum’s focused product pipeline that targets serious brain diseases such as schizophrenia, Alzheimer’s disease and frontotemporal dementia,” said Deborah Dunsire, M.D., president and CEO of Forum Pharmaceuticals.
“With our lead product candidate, encenicline, in two large phase III clinical trials for schizophrenia and Alzheimer’s disease, our genetically-targeted therapy, FRM-0334, in a phase II trial for a genetic variant of frontotemporal dementia, as well as our robust drug discovery efforts, we need to plan for Forum’s future growth as we bring new medicines to patient,” said Dunsire.